Antigen Characterized By Name Or Molecular Weight Patents (Class 424/156.1)
-
Patent number: 7553953Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: March 4, 2008Date of Patent: June 30, 2009Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Patent number: 7550568Abstract: The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.Type: GrantFiled: February 28, 2008Date of Patent: June 23, 2009Assignee: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventor: Soldano Ferrone
-
Publication number: 20090136490Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110 expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: November 10, 2005Publication date: May 28, 2009Applicant: DIADEXUS, INC.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Timothy S. Burcham, Laura Corral, Iris Simon, Jackie Papkoff
-
Patent number: 7521047Abstract: The present invention relates to polypeptide compositions which bind to cell surface epitopes and, in multivalent forms, cause or lead to the killing of cells including lymphoid tumor cells, and in the case of monovalent forms, cause immunosuppression or otherwise inhibit activation of lymphocytes. The invention further relates to nucleic acids encoding the polypeptides, methods for the production of the polypeptides, methods for killing cells, methods for immunosuppressing a patient, pharmaceutical, diagnostic and multivalent compositions and kits comprising the polypeptides and uses of the polypeptides.Type: GrantFiled: November 15, 2001Date of Patent: April 21, 2009Assignees: GPC Biotech AG, Morphosys AGInventors: Zoltan Nagy, Christoph Brunner, Michael Tesar, Elisabeth Thomassen-Wolf, Robert Rauchenberger
-
Patent number: 7517964Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: GrantFiled: May 8, 2007Date of Patent: April 14, 2009Assignee: Immunomedics, Inc.Inventors: Serengulam Govindan, Zhengxing Qu, Hans Hansen, Davd M. Goldenberg
-
Patent number: 7514078Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.Type: GrantFiled: May 30, 2003Date of Patent: April 7, 2009Assignee: Cornell Research Foundation, Inc.Inventors: Neil H. Bander, Francis J. Carr, Anita Hamilton
-
Patent number: 7501122Abstract: The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations.Type: GrantFiled: September 9, 2005Date of Patent: March 10, 2009Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
-
Patent number: 7498304Abstract: Hedgehog agonists and antagonists can be used to regulate angiogenesis, and to prevent angiogenesis driven pathologies. Furthermore, hedgehog agonists and antagonists have utility in modulating tissue repair and in the treatment of many forms of cancer.Type: GrantFiled: August 29, 2003Date of Patent: March 3, 2009Assignee: Curis, Inc.Inventors: Karen Kotkow, Lee L. Rubin
-
Publication number: 20090053136Abstract: Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1 Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1 protein-expressing cells are described.Type: ApplicationFiled: April 8, 2008Publication date: February 26, 2009Applicant: NUVELO, INC.Inventors: Douglas Dedera, Jian-Rui Wang, Peter C.R. Emtage
-
Publication number: 20090041773Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.Type: ApplicationFiled: May 18, 2006Publication date: February 12, 2009Applicants: Novartis Vaccines and Diagnostics , Inc., XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
-
Patent number: 7485296Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: December 21, 2004Date of Patent: February 3, 2009Assignees: The Regents of the University of California, Agensys, Inc.Inventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
-
Publication number: 20090028872Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.Type: ApplicationFiled: September 26, 2006Publication date: January 29, 2009Inventors: Jonathan Alexander Terret, Li-Sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
-
Publication number: 20080260748Abstract: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody.Type: ApplicationFiled: May 11, 2006Publication date: October 23, 2008Applicant: Oncotherapy Science, Inc.Inventors: Takashi Iwamoto, Megumi Yoshikawa
-
Patent number: 7435797Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chainsType: GrantFiled: April 9, 2003Date of Patent: October 14, 2008Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
-
Patent number: 7435412Abstract: The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are useful in studying and treating cancer.Type: GrantFiled: March 4, 2003Date of Patent: October 14, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, John McWhirter
-
Patent number: 7435416Abstract: The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.Type: GrantFiled: September 8, 2004Date of Patent: October 14, 2008Assignee: Genetech, Inc.Inventors: Brigitte Devaux, Gilbert-Andre Keller, Hartmut Koeppen, Lawrence A. Lasky
-
Publication number: 20080241066Abstract: The invention relates to antibodies or antigen-binding fragments thereof which bind PRL-3 without binding to and cross-reacting with PRL-1 or PRL-2. The invention also relates to methods of identifying and treating invasive or metastatic cancer using the anti-PRL-3 antibodies and the use of anti-PRL-3 antibodies in prognostic, preventative, diagnostic and other therapeutic methods.Type: ApplicationFiled: July 26, 2007Publication date: October 2, 2008Inventors: Chengchao Shou, Lirong Peng, Xiao-Jia Chang
-
Patent number: 7429381Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.Type: GrantFiled: September 1, 2005Date of Patent: September 30, 2008Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Patent number: 7427403Abstract: This invention relates to compositions and methods comprising “lymphotoxin-? receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.Type: GrantFiled: February 15, 2002Date of Patent: September 23, 2008Assignee: Biogen Idec MA Inc.Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
-
Patent number: 7422739Abstract: Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.Type: GrantFiled: July 25, 2001Date of Patent: September 9, 2008Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
-
Patent number: 7416726Abstract: The present invention is related to enhancing the function of anti-tumor antibodies by regulating Fc?RIIB-mediated activity. In particular, disrupting SHIP activation by Fc?RIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to Fc?RIIB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting Fc?RIIB molecule is a potent regulator of cytotoxicity in vivo.Type: GrantFiled: April 13, 2001Date of Patent: August 26, 2008Assignee: The Rockefeller UniversityInventor: Jeffrey V. Ravetch
-
Patent number: 7399470Abstract: A sandwich immunoassay kit for detecting ciguatoxins based on a combination of two anti-ciguatoxin CTX3C monoclonal antibodies produced by hybridomas, 3D11 (deposited at IPOD, AIST under accession number FMRM PB-8293) and 10C9 (FMRM PB-8292). In particular, one of the antibodies is labeled and each of them binds specifically to a different site of ciguatoxin CTX3C.Type: GrantFiled: March 10, 2003Date of Patent: July 15, 2008Assignee: Japan Science and Technology AgencyInventors: Masahiro Hirama, Hiroki Oguri, Ikuo Fujii, Takeshi Tsuburaya
-
Patent number: 7390489Abstract: The present invention relates to a monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes, a hybridoma cell producing the monoclonal antibody, a test kit comprising the monoclonal antibody, and a method for detecting Listeria monocytogenes using the monoclonal antibody. The inventive monoclonal selectively recognizes only Listeria monocytogenes, so that the use of such an antibody allows for rapid determination of the food contamination with these bacteria pathogenic to humans.Type: GrantFiled: October 8, 2004Date of Patent: June 24, 2008Assignee: Komed Co., Ltd.Inventors: Byung Soo Youn, Young Soo Yang, Nam Seok Lee, Kang Yeol Yu, Young Soon Noh, Hong Je Park, Moon Yeon Youn, Min Sup Chung, Sung Shik Min, Jae Jun Jeong
-
Patent number: 7387772Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: April 5, 2002Date of Patent: June 17, 2008Assignee: Immunimedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Publication number: 20080131443Abstract: The invention concerns methods and compositions for initiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.Type: ApplicationFiled: October 31, 2007Publication date: June 5, 2008Applicant: AltaRex Medical Corp.Inventors: Ragupathy Madiyalakan, Antoine A. Noujaim, Richard P. Baum
-
Patent number: 7374765Abstract: Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.Type: GrantFiled: October 1, 2004Date of Patent: May 20, 2008Assignee: Bio-Rad Laboratories, Inc.Inventors: John N. Feder, Randall C. Schatzman, Zenta Tsuchihashi
-
Patent number: 7371379Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.Type: GrantFiled: June 20, 2003Date of Patent: May 13, 2008Assignee: Genentech, Inc.Inventors: Sharon A. Baughman, Steven Shak
-
Patent number: 7368428Abstract: Methods and compositions for restoring sensitivity to the antitumorigenic effects of antiestrogen therapy and/or cytotoxic therapy and inducing cell apoptosis are provided. Contacting tumor cells to GP88 antagonists (e.g., anti-GP88 antibodies, anti-GP88 antisense nucleic acids, GP88 siRNA, and small molecules) induces apoptosis and restores sensitivity to the antitumorigenic effects of antiestrogen therapy and cytotoxic therapy.Type: GrantFiled: June 23, 2004Date of Patent: May 6, 2008Assignee: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 7344714Abstract: The present invention is related to a method for producing motif-specific, context-independent antibodies which are specific to at least one modified amino acid residue in the context of variable surrounding amino acid or peptide sequences. The method is particularly useful in producing antibodies which recognize phosphorylated serine, threonine, and tyrosine, or acetylated lysine, as well as other modified amino acids-containing motifs of one or more amino acids.Type: GrantFiled: May 7, 2002Date of Patent: March 18, 2008Assignee: Cell Signaling Technology, IncInventors: Michael J. Comb, Yi Tan
-
Patent number: 7318924Abstract: An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitizing a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.Type: GrantFiled: March 26, 2002Date of Patent: January 15, 2008Assignee: The Austin Research InstituteInventors: Ian Farquhar Campbell McKenzie, Pei-Xiang Xing, Xiu Feng Hu
-
Patent number: 7300765Abstract: The present invention relates to new uses of Solute Carrier 6 (SC6), a taurine transporter, in the diagnosis, screening, treatment and prophylaxis of hypoxia related conditions e.g. cancer. Compositions comprising the protein, such as vaccines and agents that modulate the protein expression or activity, including antibodies that are immunospecific for the protein, are also provided.Type: GrantFiled: April 2, 2003Date of Patent: November 27, 2007Assignee: UCB Pharma S.A.Inventor: Sonal Patel
-
Patent number: 7264807Abstract: This invention pertains to a method for treating ulcerative colitis. Specifically, the method comprises orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of an antibody which binds to a tropomyosin isoform associated with ulcerative colitis. In another embodiment, the invention pertains to a method for treating ulcerative colitis in a human which comprises the steps of (a) obtaining from a human a colon epithelial cell extract containing a tropomyosin isoform associated with ulcerative colitis; (b) purifying the tropomyosin isoform until the tropomyosin isoform is substantially homogeneous; (c) developing an antibody which binds to the tropomyosin isoform; and (d) orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of the antibody to bind to the tropomyosin isoform associated with ulcerative colitis.Type: GrantFiled: May 1, 2003Date of Patent: September 4, 2007Assignee: University of Medicine and Dentistry of New JerseyInventor: Kiron M. Das
-
Patent number: 7238785Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: GrantFiled: March 3, 2003Date of Patent: July 3, 2007Assignee: Immunomedics, Inc.Inventors: Serengulam Govindan, Zhengxing Qu, Hans Hansen, David Goldenberg
-
Patent number: 7227002Abstract: The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions comprising the aforementioned antibodies or fragments thereto.Type: GrantFiled: April 14, 1998Date of Patent: June 5, 2007Assignee: Micromet AGInventors: Peter Kufer, Tobias Raum
-
Patent number: 7211257Abstract: The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF).Type: GrantFiled: February 9, 2004Date of Patent: May 1, 2007Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Kenneth Beaman
-
Patent number: 7198787Abstract: A method for killing unwanted target cells in a cell population comprising nucleated cells harvested from peripheral blood, or CD-34+ or similar early progenitor cells selected from the above nucleated cells or from bone marrow aspirates, in which method the cell population is in vitro or in vivo exposed to two or more immunotoxins selectively killing the malignant cells, is described. Furthermore the invention relates to the mixture of immunotixins, the use of the mixture and a kit for performing the method.Type: GrantFiled: March 12, 1997Date of Patent: April 3, 2007Assignee: Oystein FodstadInventors: Oystein Fodstad, Gunnar Kvalbeim, Meng yu Wang, Olav Engebraten, Siri Juell
-
Patent number: 7192586Abstract: Methods and compositions for treating, preventing, or diagnosing epidermal or dermal disorders, e.g., psoriasis, are disclosed. The methods and compositions of the invention use binding agents, e.g., antibodies, specific for the extracellular domain of human prostate specific membrane antigen (PSMA).Type: GrantFiled: May 30, 2002Date of Patent: March 20, 2007Assignee: Cornell Research Foundation, Inc.Inventor: Neil Bander
-
Patent number: 7189397Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.Type: GrantFiled: August 22, 2003Date of Patent: March 13, 2007Assignee: Arius Research Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7189824Abstract: A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing the monoclonal antibody, pharmaceutical agents comprising the monoclonal antibody, as well as pharmaceutical or diagnostic agents comprising a conjugate of the monoclonal antibody and another conjugating molecule.Type: GrantFiled: November 8, 2001Date of Patent: March 13, 2007Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tadanori Mayumi, Shinsaku Nakagawa, Yasuo Tsutsumi, Iwao Ohizumi
-
Patent number: 7189816Abstract: An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23–33 (CDR1), 49–55 (CDR2), 88–98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158–162 (CDR1), 177–193 (CDR2, 226–238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.Type: GrantFiled: October 26, 2000Date of Patent: March 13, 2007Assignee: Active Biotech ABInventors: Thomas Brodin, Pia J. Karlström, Lennart G. Ohlsson, Jesper M. Tordsson, Philip P. Kearney, Bo H. K. Nilson
-
Patent number: 7183388Abstract: This invention provides novel antibodies that specifically bind to the cancer antigen MUC-1. The antibodies are useful targeting moieties for specifically directing imaging agents and various therapeutic moieties to a cancer.Type: GrantFiled: May 9, 2003Date of Patent: February 27, 2007Assignee: The Regents of the University of CaliforniaInventors: Sally Joan Denardo, Michelle Denise Winthrop, Gerald Louis Denardo, Cheng-Yi Xiong
-
Patent number: 7151169Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF?1 and are useful in treating conditions associated with excess TGF?1 activity, such as fibrosis, immune responses and tumor progression.Type: GrantFiled: September 13, 2002Date of Patent: December 19, 2006Assignee: Cambridge Antibody Technology LimitedInventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
-
Patent number: 7125541Abstract: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.Type: GrantFiled: December 14, 2000Date of Patent: October 24, 2006Assignee: The University of Texas System Board of RegentsInventors: Philip E. Thorpe, Francis J. Burrows
-
Patent number: 7118741Abstract: There is disclosed a synthetic cross-linker protein capable of binding a molecule or macromolecular species to a transcytosis receptor for transport of the molecule or macromolecule species across a mucous membrane, said cross-linker protein comprising a first binding region capable of binding selectively to a site on the said molecule or macromolecular species to be transported and a second binding region capable of binding selectively to a site on said receptor, wherein the first binding region is the antigen-binding site of a first antibody molecule having specificity for an antigenic site on said molecule or macromolecular species to be transported and the second binding region is the antigen-binding site of a second antibody molecule which has specificity for an antigenic site on the said transcytosis receptor.Type: GrantFiled: May 13, 1996Date of Patent: October 10, 2006Assignee: The National Blood AuthorityInventors: Jacqueline Elizabeth Mary Gilmour, David Joseph Unsworth
-
Patent number: 7115716Abstract: The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.Type: GrantFiled: November 19, 2002Date of Patent: October 3, 2006Assignee: Eli Lilly and CompanyInventor: Jeffry D. Watkins
-
Patent number: 7115577Abstract: Development of colorectal neoplasia in a patient subject or predisposed to colorectal neoplasia is reduced by the steps of (a) determining a patient is subject or predisposed to colorectal neoplasia; and (b) enterically delivering into the gut of the person an effective amount of an aminoglycoside antibiotic having poor gut absorption, whereby the development of the colorectal neoplasia is reduced as compared with otherwise similar non-treated patients.Type: GrantFiled: December 27, 2004Date of Patent: October 3, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan Graff, Matthew Wieduwilt
-
Patent number: 7112317Abstract: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.Type: GrantFiled: February 27, 2003Date of Patent: September 26, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Francis J. Burrows
-
Patent number: 7097836Abstract: The present invention provides a method for enhancing the efficacy of chemotherapeutic agents for therapy of cancer and other angiogenesis-associated diseases such as rheumatoid arthritis. The method comprises the steps of administering to an individual in need of treatment, a combination of an anti-endoglin antibody and a chemotherapeutic agent. The anti-endoglin antibody and the chemotherapeutic agent may be administered sequentially or concurrently.Type: GrantFiled: October 22, 2003Date of Patent: August 29, 2006Assignee: Health Research, Inc.Inventor: Ben K. Seon
-
Patent number: 7094404Abstract: The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. 90Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.Type: GrantFiled: June 7, 1995Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Thomas A. Waldmann
-
Patent number: RE40535Abstract: An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with amino acid present in equivalent positions in antibodies of a species other than munne, and the constant regions of a human antibody. The antibody may be labeled and/or glycosylated, and is presented as a composition with a carrier. The anti-KC-4 monoclonal antibody is used in diagnostic kits for cancer and in in vivo methods of imaging and treating a primary or metastasized cancer, and in vitro diagnosis and ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the monoclonal antibody, and a hybrid vector carrying the nucleotides and transfected cells express the peptides.Type: GrantFiled: May 14, 2002Date of Patent: October 7, 2008Assignee: IBC Pharmaceuticals, Inc.Inventors: Fernando J. R. do Couto, Roberto L. Ceriani, Jerry A. Peterson